Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people

Ronald G. Hall, Mark A. Swancutt, Claudia Meek, Richard D. Leff, Tawanda Gumbo

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We conducted a prospective study of 18 adult volunteers (male-to-female ratio of 1) whose body mass index fell into categories of<25, 25 to 40, or>40 kg/m 2, who received a single oral dose of 1,600 mg ethambutol. Only individuals with normal renal function were recruited. The minimum body mass (M) was 45.6 kg, the median was 90.8 kg, and the maximum weight was 160.4 kg. Ethambutol pharmacokinetics were best described by a two-compartment model. Inclusion of weight as a covariate dramatically improved the model, with a relative likelihood approaching infinity. The typical clearance was 42.6 liters/h. Ethambutol systemic clearance was proportional to (M/45.6) 3/4 and thus obeyed fractal geometry-based laws. This means that the area under the concentration-time curve (AUC) actually decreased for obese patients compared to that for leaner patients, reducing chances of concentration-dependent toxicity. On the other hand, such reduced AUCs could lead to therapy failure. Thus, new and individualized ethambutol dosing regimens need to be designed for obese and extremely obese patients.

Original languageEnglish (US)
Pages (from-to)1502-1507
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Ethambutol
Pharmacokinetics
Weights and Measures
Fractals
Area Under Curve
Volunteers
Body Mass Index
Prospective Studies
Kidney
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. / Hall, Ronald G.; Swancutt, Mark A.; Meek, Claudia; Leff, Richard D.; Gumbo, Tawanda.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 3, 03.2012, p. 1502-1507.

Research output: Contribution to journalArticle

Hall, Ronald G. ; Swancutt, Mark A. ; Meek, Claudia ; Leff, Richard D. ; Gumbo, Tawanda. / Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. In: Antimicrobial Agents and Chemotherapy. 2012 ; Vol. 56, No. 3. pp. 1502-1507.
@article{18910e852cc843dab18dbbb674e55200,
title = "Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people",
abstract = "We conducted a prospective study of 18 adult volunteers (male-to-female ratio of 1) whose body mass index fell into categories of<25, 25 to 40, or>40 kg/m 2, who received a single oral dose of 1,600 mg ethambutol. Only individuals with normal renal function were recruited. The minimum body mass (M) was 45.6 kg, the median was 90.8 kg, and the maximum weight was 160.4 kg. Ethambutol pharmacokinetics were best described by a two-compartment model. Inclusion of weight as a covariate dramatically improved the model, with a relative likelihood approaching infinity. The typical clearance was 42.6 liters/h. Ethambutol systemic clearance was proportional to (M/45.6) 3/4 and thus obeyed fractal geometry-based laws. This means that the area under the concentration-time curve (AUC) actually decreased for obese patients compared to that for leaner patients, reducing chances of concentration-dependent toxicity. On the other hand, such reduced AUCs could lead to therapy failure. Thus, new and individualized ethambutol dosing regimens need to be designed for obese and extremely obese patients.",
author = "Hall, {Ronald G.} and Swancutt, {Mark A.} and Claudia Meek and Leff, {Richard D.} and Tawanda Gumbo",
year = "2012",
month = "3",
doi = "10.1128/AAC.05623-11",
language = "English (US)",
volume = "56",
pages = "1502--1507",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people

AU - Hall, Ronald G.

AU - Swancutt, Mark A.

AU - Meek, Claudia

AU - Leff, Richard D.

AU - Gumbo, Tawanda

PY - 2012/3

Y1 - 2012/3

N2 - We conducted a prospective study of 18 adult volunteers (male-to-female ratio of 1) whose body mass index fell into categories of<25, 25 to 40, or>40 kg/m 2, who received a single oral dose of 1,600 mg ethambutol. Only individuals with normal renal function were recruited. The minimum body mass (M) was 45.6 kg, the median was 90.8 kg, and the maximum weight was 160.4 kg. Ethambutol pharmacokinetics were best described by a two-compartment model. Inclusion of weight as a covariate dramatically improved the model, with a relative likelihood approaching infinity. The typical clearance was 42.6 liters/h. Ethambutol systemic clearance was proportional to (M/45.6) 3/4 and thus obeyed fractal geometry-based laws. This means that the area under the concentration-time curve (AUC) actually decreased for obese patients compared to that for leaner patients, reducing chances of concentration-dependent toxicity. On the other hand, such reduced AUCs could lead to therapy failure. Thus, new and individualized ethambutol dosing regimens need to be designed for obese and extremely obese patients.

AB - We conducted a prospective study of 18 adult volunteers (male-to-female ratio of 1) whose body mass index fell into categories of<25, 25 to 40, or>40 kg/m 2, who received a single oral dose of 1,600 mg ethambutol. Only individuals with normal renal function were recruited. The minimum body mass (M) was 45.6 kg, the median was 90.8 kg, and the maximum weight was 160.4 kg. Ethambutol pharmacokinetics were best described by a two-compartment model. Inclusion of weight as a covariate dramatically improved the model, with a relative likelihood approaching infinity. The typical clearance was 42.6 liters/h. Ethambutol systemic clearance was proportional to (M/45.6) 3/4 and thus obeyed fractal geometry-based laws. This means that the area under the concentration-time curve (AUC) actually decreased for obese patients compared to that for leaner patients, reducing chances of concentration-dependent toxicity. On the other hand, such reduced AUCs could lead to therapy failure. Thus, new and individualized ethambutol dosing regimens need to be designed for obese and extremely obese patients.

UR - http://www.scopus.com/inward/record.url?scp=84857183281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857183281&partnerID=8YFLogxK

U2 - 10.1128/AAC.05623-11

DO - 10.1128/AAC.05623-11

M3 - Article

VL - 56

SP - 1502

EP - 1507

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -